{"database": "lobbying", "table": "lobbying_activities", "rows": [[1986622, "7830c1a3-b481-425a-ba64-4874b49489e9", "Q2", "RED+BLUE STRATEGIES", 400693064, "COHERUS BIOSCIENCES", 2017, "second_quarter", "PHA", "S. 771 - A bill to improve access to affordable prescription drugs - issues related to ensuring a healthy market for biosimilar medications. \n\nS.934 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications. \n\nH.R. 2797 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications. \n\nIssues related to the treatment of biosimilar medications in Medicare Part B and D programs. \n\nIssues related to the maintenance of current IPR laws.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", 60000, null, 0, 0, "2017-07-13T13:01:35.477000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1986622"], "units": {}, "query_ms": 2.212024002801627, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}